XRAY or MMSI: Which Is the Better Value Stock Right Now?

An analysis comparing Dentsply International (XRAY) and Merit Medical (MMSI) in the Medical - Dental Supplies sector identifies XRAY as the superior value stock. XRAY exhibits significantly more attractive valuation metrics, including a forward P/E of 7.53, a PEG ratio of 1.02, and a P/B of 1.42, compared to MMSI's respective 24.98, 2.46, and 3.37. This is further supported by XRAY's Zacks Rank #2 (Buy) and an 'A' Value grade, indicating a stronger earnings outlook and overall better valuation compared to MMSI's Zacks Rank #3 (Hold) and 'C' grade.

Analysis

A comparative analysis within the Medical - Dental Supplies sector reveals that Dentsply International (XRAY) presents a significantly more compelling value proposition than Merit Medical (MMSI). This conclusion is supported by key quantitative metrics and a more favorable analyst outlook. XRAY trades at a forward P/E ratio of 7.53, substantially below MMSI's 24.98. Furthermore, XRAY's PEG ratio of 1.02 indicates a reasonable valuation relative to its expected earnings growth, in stark contrast to MMSI's higher PEG of 2.46. The valuation gap is also evident in the price-to-book ratios, with XRAY at 1.42 versus MMSI's 3.37. These metrics are reinforced by the proprietary Zacks Rank system, which assigns XRAY a #2 (Buy) rank, signaling positive earnings estimate revisions, and an 'A' grade for Value. Conversely, MMSI holds a #3 (Hold) rank and a 'C' grade for Value, suggesting a more stagnant earnings outlook and less attractive valuation.

Key Decisions for Investors

• Value-focused investors should consider Dentsply International (XRAY) as a superior opportunity due to its strong buy-rated earnings outlook and significant valuation discount on P/E, PEG, and P/B metrics compared to its peer.
• Investors currently holding Merit Medical (MMSI) should note its premium valuation and neutral 'Hold' rating, which suggests potential underperformance relative to more attractively priced competitors in the sector.
• The primary driver highlighted is the trend in earnings estimate revisions, making it critical to monitor upcoming earnings reports and analyst sentiment for both companies to confirm the persistence of this value thesis.